Chronic kidney disease, heart failure and neprilysin inhibition

Chronic kidney disease, heart failure and neprilysin inhibition

Patients with chronic kidney disease are at increased risk of cardiovascular disease and this often manifests clinically like heart failure. Conversely, patients with heart failure frequently have reduced kidney function. The links between the kidneys and cardiovascular system are being elucidated,...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Haynes, R, Zhu, D, Judge, P, Herrington, W, Kalra, P, Baigent, C
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Oxford University Press 2019

समान संसाधन

Neprilysin inhibition in chronic kidney disease.
द्वारा: Judge, P, और अन्य
प्रकाशित: (2014)

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease
द्वारा: Judge, PK, और अन्य
प्रकाशित: (2021)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
द्वारा: Zhu, D, और अन्य
प्रकाशित: (2025)

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease
द्वारा: Zhu, D, और अन्य
प्रकाशित: (2025)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
द्वारा: Zhu, P, और अन्य
प्रकाशित: (2020)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
द्वारा: Preiss, D, और अन्य
प्रकाशित: (2022)

The role of lipoprotein(a) in chronic kidney disease
द्वारा: Hopewell, J, और अन्य
प्रकाशित: (2018)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
द्वारा: Mayne, K, और अन्य
प्रकाशित: (2024)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
द्वारा: Staplin, N, और अन्य
प्रकाशित: (2022)

Bioimpedance indices of fluid overload and cardiorenal outcomes in heart failure and chronic kidney disease: a systematic review
द्वारा: Mayne, KJ, और अन्य
प्रकाशित: (2022)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
द्वारा: Staplin, N, और अन्य
प्रकाशित: (2023)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2018)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
द्वारा: Mayne, K, और अन्य
प्रकाशित: (2023)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
द्वारा: Schlackow, I, और अन्य
प्रकाशित: (2017)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
द्वारा: Mihaylova, B, और अन्य
प्रकाशित: (2019)

Lipids in chronic kidney disease.
द्वारा: Lewis, D, और अन्य
प्रकाशित: (2010)

Empagliflozin in patients with chronic kidney disease
द्वारा: Herrington, WG, और अन्य
प्रकाशित: (2022)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2018)

Metformin: the safest hypoglycaemic agent in chronic kidney disease?
द्वारा: Nye, H, और अन्य
प्रकाशित: (2011)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2016)

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2016)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
द्वारा: Mafham, M, और अन्य
प्रकाशित: (2017)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the study of heart and renal protection
द्वारा: Reith, C, और अन्य
प्रकाशित: (2017)

Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme
द्वारा: Perera, R, और अन्य
प्रकाशित: (2021)

Biliary tract and liver complications in polycystic kidney disease
द्वारा: Judge, P, और अन्य
प्रकाशित: (2017)

Which cardiovascular risk factors matter in chronic kidney disease?
द्वारा: Baigent, C, और अन्य
प्रकाशित: (2007)

Commentary: Controversies in NICE guidance on chronic kidney disease.
द्वारा: Landray, M, और अन्य
प्रकाशित: (2008)

Commentary: Controversies in NICE guidance on chronic kidney disease
द्वारा: Landray, M, और अन्य
प्रकाशित: (2008)

Metformin use in chronic kidney disease: new evidence to guide dosing.
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2013)

Benefits of lowering cholesterol in chronic kidney disease Reply
द्वारा: Baigent, C, और अन्य
प्रकाशित: (2011)

Long-term effects of empagliflozin in patients with chronic kidney disease
द्वारा: Herrington, WG, और अन्य
प्रकाशित: (2024)

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)
द्वारा: Herrington, WG, और अन्य
प्रकाशित: (2023)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
द्वारा: Judge, PK, और अन्य
प्रकाशित: (2024)

Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy.
द्वारा: Miners, J, और अन्य
प्रकाशित: (2006)

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP).
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2014)

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP)
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2014)

Premature cardiovascular disease in chronic renal failure.
द्वारा: Baigent, C, और अन्य
प्रकाशित: (2000)

Impact of primary kidney disease on the effects of empagliflozin in patients with CKD
द्वारा: Judge, PK, और अन्य
प्रकाशित: (2023)

Chronic kidney disease
द्वारा: de Lusignan, S
प्रकाशित: (2006)

Kidney failure with a diagnostic chest radiograph.
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2012)